Genetic Engineering, Humankind Creeps Toward A 'Planet Of The Apes'
By Laurent Alexandre,
World Crunch
| 04. 07. 2015
PARIS — Half-animal, half-human? The astounding developments in nanotechnology, biotechnology, information technology and cognitive science (NBIC) are posing problems that we thought only existed in science fiction.
Recent studies have brought us closer to Planet of the Apes, written by French novelist Pierre Boulle in 1963. In three experiments, the last one of which was published in Current Biology last month, scientists have improved the intellectual capacities of mice by modifying their DNA sequences with segments of human chromosomes or by injecting them with human brain glial cells.
These modified animals have bigger brains and can perform difficult tasks more quickly. The DNA sequences that were successfully modified are involved in language and brain size in humans. This comes after a study on successful genetic modifications on two small monkeys was published in Nature in March of last year. Meaning that the success of cognitive improvement of mice will soon be verified in monkeys.
These manipulations were achieved with DNA-modifying enzymes. For about $12, a biology student these days can create these enzymes and conduct genetic engineering, making it...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...